Published: 1 December 2023
Author(s): Rosalinda Madonna, Mattia Alberti, Filippo Biondi, Riccardo Morganti, Roberto Badagliacca, Carmine Dario Vizza, Raffaele De Caterina
Issue: May 2024
Section: Original Article

Chronic thromboembolic pulmonary disease (CTEPD) [1] is a newly described disease entity belonging to a broader group of diseases affecting the pulmonary arterial vasculature as a result of PE [1,2]. CTEPD is defined as imaging evidence of persistent pulmonary arterial obstruction at any level despite at least 4 months of effective anticoagulation, combined with symptoms of cardiorespiratory impairment without resting pulmonary hypertension (PH) [3]. Chronic thromboembolic pulmonary hypertension (CTEPH) is a CTEPD associated with PH at rest, while the “post-PE-syndrome” (PPES) refers to all PE patients with persistently declined functional status in the absence of any thrombotic obstruction in the pulmonary vasculature [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.